Heart Failure: Preventable with Scientific Advances
SGLT2 Inhibitors Show Benefit in Heart Failure Patients With preserved Ejection Fraction
Table of Contents
New data presented at the European Society of Cardiology (ESC) Congress 2023 reinforce the growing role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of heart failure, even in patients with preserved ejection fraction (HFpEF). The EMPEROR-preserved trial’s extended follow-up,along with insights from other studies,suggest these medications offer significant clinical benefits beyond their initial indications for diabetes and cardiovascular risk reduction.
Expanding the Role of SGLT2 Inhibitors
For years, treatment options for HFpEF have been limited. Unlike heart failure with reduced ejection fraction (HFrEF), where therapies like ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists have demonstrated clear mortality benefits, HFpEF has proven more challenging to address. SGLT2 inhibitors, initially developed for type 2 diabetes, have emerged as a promising new avenue for improving outcomes in this population.
“The paradigm shift is really happening now,” said Dr. Deepak Lala, a cardiologist at Mount Sinai in New York City, discussing the latest findings. “We’re seeing consistent data across multiple trials that SGLT2 inhibitors are beneficial in HFpEF, and that’s incredibly exciting.”
EMPEROR-Preserved: Long-Term Outcomes
The EMPEROR-preserved trial, which investigated the SGLT2 inhibitor empagliflozin, initially showed a modest but significant benefit in reducing hospitalization for heart failure and cardiovascular death in patients with HFpEF. The extended follow-up presented at ESC 2023 revealed that these benefits appear to be sustained over time.Specifically, the analysis showed:
A continued reduction in the risk of heart failure hospitalization and cardiovascular death.
A signal of potential long-term benefit on all-cause mortality, although further investigation is needed.
consistent benefits across various subgroups of patients, including those with and without diabetes.
These findings suggest that the positive effects of empagliflozin aren’t simply due to short-term improvements in symptoms but rather reflect a more essential impact on the underlying disease process.
mechanisms of Benefit: Beyond Glucose Control
While SGLT2 inhibitors were initially thought to work primarily by lowering blood glucose, it’s now clear that their benefits extend far beyond glycemic control. Several mechanisms are believed to contribute to their cardioprotective effects:
Diuretic Effect: SGLT2 inhibitors promote glucose excretion in the urine, leading to a mild diuretic effect that can reduce fluid overload and alleviate heart failure symptoms.
Weight Loss: The diuretic effect and caloric loss through glucose excretion contribute to modest weight loss, which can improve cardiac function.
Reduced Blood Pressure: SGLT2 inhibitors can lead to a slight reduction in blood pressure, further easing the burden on the heart.
Improved Cardiac Metabolism: Emerging evidence suggests that SGLT2 inhibitors may directly improve cardiac metabolism by shifting the heart’s energy source from glucose to fatty acids, potentially enhancing efficiency.
Reduced Inflammation: SGLT2 inhibitors may have anti-inflammatory effects, which could contribute to their cardioprotective properties.
Implications for Clinical Practice
The growing body of evidence supporting SGLT2 inhibitors in HFpEF is prompting clinicians to reconsider their approach to managing this challenging condition.
“We’re now at a point where we should seriously consider SGLT2 inhibitors for a broader range of patients with HFpEF,” Dr. Lala explained. “The benefits appear to outweigh the risks,and these medications offer a much-needed therapeutic option for a population that has historically had limited choices.”
Though,it’s critically important to note that SGLT2 inhibitors are not a “one-size-fits-all” solution. Careful patient selection and consideration of potential side effects, such as genital infections and